Isolating aminoarginine and use to block nitric oxide formation in body
AssigneeCornell Research Foundation, Inc.
InventorOwen W. Griffith
Life of this patent
Estimating the term…
Loading patent…
AssigneeCornell Research Foundation, Inc.
InventorOwen W. Griffith
Estimating the term…
Pharmaceutically pure physiologically active N.sup.G -aminoarginine (i.e., the L or D,L form) or pharmaceutically acceptable salt thereof is administered in a nitric oxide synthesis inhibiting amount to a subject in need of such inhibition (e.g. a subject with low blood pressure or needing immunosuppressive effect) or is added to a medium containing isolated organs, intact cells, cell homogenates or tissue homogenates in an amount sufficient to inhibit nitric oxide formation to elucide or control the biosynthesis, metabolism or physiological role of nitric oxide. N.sup.G -amino-L-arginine is prepared and isolated as a pharmaceutically pure compound by reducing N.sup.G -nitro-L-arginine, converting L-arginine by-product to L-ornithine with arginase and separating N.sup.G -amino-L-arginine from the L-ornithine. N.sup.G -amino-D,L-arginine is prepared in similar fashion starting with N.sup.G -nitro-D,L-arginine.
Pharmaceutically pure N.sup.G -amino-L-arginine in the free base form.
Pharmaceutically pure, pharmaceutically acceptable acid addition salt of N.sup.G -amino-L-arginine or mixtures thereof with N.sup.G -amino-L-arginine in the free base form.
A composition containing more than 99.9% by weight (on a water-free basis) of agent selected from the group consisting of N.sup.G -aminoarginine containing L-enantiomer thereof and pharmaceutically acceptable acid addition salts of said N.sup.G -aminoarginine.
Dependencies are inferred from the claim text.